SAFETY DATA SHEET  
according to GB/T 16483 and GB/T 17519

Golimumab Formulation

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Golimumab Formulation

Manufacturer or supplier’s details

Company : MSD
Address : 199 Wenhai North Road 
HEDA, Hangzhou - Zhejiang Province - CHINA 310018
Telephone : 908-740-4000
Emergency telephone number : 86-571-87268110
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance : Aqueous solution
Colour : opalescent
Odour : No data available

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

GHS Classification

Respiratory sensitisation : Category 1

GHS label elements

Hazard pictograms : 

Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Precautionary statements : 

Prevention:
P261 Avoid breathing mist or vapours.
P284 Wear respiratory protection.

Response:
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P342 + P311 If experiencing respiratory symptoms: Call a
POISON CENTER/doctor.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards
Not classified based on available information.

Health hazards
May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Environmental hazards
Not classified based on available information.

Other hazards which do not result in classification
None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Golimumab</td>
<td>476181-74-5</td>
<td>&gt;= 10 -&lt; 20</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.

In case of skin contact : Wash with water and soap as a precaution.
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive Airways dysfunction syndrome).

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.
Golimumab Formulation

5. FIREFIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Sulphur oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling
Golimumab Formulation

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
- Avoid inhalation of vapour or mist.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Already sensitised individuals should consult their physician regarding working with respiratory irritants or sensitisers.
- Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact: Oxidizing agents

Storage

Conditions for safe storage:
- Keep in properly labelled containers.
- Keep tightly closed.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents

Packaging material: Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Golimumab</td>
<td>476181-74-5</td>
<td>TWA</td>
<td>12 µg/m3</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures: Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations.

Personal protective equipment

Respiratory protection:
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  - Filter type: Particulates type
  - Eye/face protection: Wear the following personal protective equipment:
    - Safety glasses
  - Skin and body protection: Skin should be washed after contact.

Hand protection
- Material: Chemical-resistant gloves

Remarks: Choose gloves to protect hands against chemicals depending...
on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>Aqueous solution</td>
</tr>
<tr>
<td>Colour</td>
<td>Opalescent</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>5.5</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td></td>
</tr>
<tr>
<td>Water solubility</td>
<td>Soluble</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>No data available</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Golimumab Formulation

Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
  Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac-
tions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition
products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
  Skin contact
  Ingestion
  Eye contact

Acute toxicity
Not classified based on available information.

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Golimumab:
Exposure routes : Inhalation
Assessment: May cause sensitisation by inhalation.

**Germ cell mutagenicity**
Not classified based on available information.

**Carcinogenicity**
Not classified based on available information.

**Reproductive toxicity**
Not classified based on available information.

**Components:**

**Golimumab:**

**Effects on fertility**
- Test Type: Fertility/early embryonic development
  - Species: Mouse, male
  - Application Route: Intravenous injection
  - Dose: 40 milligram per kilogram
  - Duration of Single Treatment: 11 Weeks
  - Frequency of Treatment: 1 days/week
  - Fertility: NOAEL Parent: 40 mg/kg body weight

- Test Type: Fertility/early embryonic development
  - Species: Mouse, female
  - Application Route: Intravenous injection
  - Dose: 40 milligram per kilogram
  - Duration of Single Treatment: 3 Weeks
  - Frequency of Treatment: 1 days/week
  - Fertility: NOAEL Parent: 40 mg/kg body weight

**Effects on foetal development**
- Test Type: Embryo-foetal development
  - Species: Monkey
  - Dose: 50 milligram per kilogram
  - Frequency of Treatment: 2 days/week
  - Teratogenicity: NOAEL: 100 mg/kg body weight
  - Embryo-foetal toxicity: NOAEL: 100 mg/kg body weight

- Test Type: Development
  - Species: Monkey
  - Dose: 50 milligram per kilogram
  - Frequency of Treatment: 2 daily
  - Developmental Toxicity: NOAEL F1: 50 mg/kg body weight

- Test Type: Embryo-foetal development
  - Species: Mouse
  - Application Route: Intravenous injection
  - Dose: 40 milligram per kilogram
  - Frequency of Treatment: 2 days
  - Teratogenicity: NOAEL: 40 mg/kg body weight
  - Embryo-foetal toxicity: NOAEL: 40 mg/kg body weight
  - Result: negative, No effects on foetal development
Golimumab Formulation

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

Golimumab:
Species : Monkey
NOAEL : 50 mg/kg
Application Route : Intravenous
Exposure time : 6 Months
Number of exposures : Intermittent

Species : Monkey
NOAEL : 25 mg/kg
Application Route : Subcutaneous
Exposure time : 6 Months

Species : Mouse
NOAEL : 40 mg/kg
Application Route : Intravenous

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Golimumab:
Inhalation : Symptoms: mild infections, upper respiratory tract infection, viral infections, bronchitis, sinusitis, fungal infections

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Golimumab:

Ecotoxicology Assessment
Acute aquatic toxicity : No data available
Chronic aquatic toxicity : No data available

Persistence and degradability
No data available
Bioaccumulative potential
No data available

Mobility in soil
No data available

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

GB 6944/12268
Not regulated as a dangerous good

Special precautions for user
Not applicable

15. REGULATORY INFORMATION

National regulatory information

Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Golimumab Formulation

Version 1.13  Revision Date: 09/13/2019  SDS Number: 26428-00014  Date of last issue: 2019/04/24

Date of first issue: 2014/10/29

16. OTHER INFORMATION

Further information

Date format: yyyy/mm/dd

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their
intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CN / EN